GLP-1 class · Triple agonist
Retatrutide
LY3437943 — Triple GIP/GLP-1/Glucagon Agonist · Triple agonist — GIPR + GLP-1R + GCGR
Quick facts
Formula
C221H343N51O68
Weight
4731.42 g/mol
Class
Triple agonist — GIPR + GLP-1R + GCGR
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide engineered as a triple agonist activating GIPR, GLP-1R, and GCGR simultaneously — the next generation beyond dual-agonist Tirzepatide.
Research mechanism
Published research has examined the following mechanisms:
- GLP-1R + GIPR activation — standard dual incretin signaling.
- GCGR activation — the novel component; glucagon receptor signaling linked to lipolysis and energy expenditure.
- Balanced agonism — relative potency across receptors characterized in binding studies.
- Adipose research — effects on lipolysis and mitochondrial biogenesis in animal models.
Note: All mechanism data is from published research. Not FDA-approved for human use.
Physical properties & handling
Reconstitute 10 mg with 2.0 mL bacteriostatic water (5 mg/mL). Swirl gently. Refrigerate; use within 28 days.
Quality specifications (Broceutical Retatrutide)
- Purity: 99.5% typical
- Identity: LC-MS/MS confirmed
- Endotoxin: <1 EU/mg
- Form: Lyophilized powder
Published research references
- Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." Cell Metab. 2022;34(9):1234-1247. PubMed PMID: 36044989
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. PubMed PMID: 37356004
- PubMed literature search https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide
Broceutical does not endorse or make claims from the above research.
Research Use Only
Retatrutide supplied by Broceutical is a research chemical for in-vitro laboratory research only. Not FDA-approved for human or veterinary use.